TOP PAGE
ENGLISH
JAPANESE
|
CONNECT WITH US:
Home
About
Services
Contact
Log in
*
Home
Press release
Nov 30, 2020 14:04 JST
Source:
Eisai
Eisai to Present Latest Data on Perampanel at the 74th American Epilepsy Society Annual Meeting
TOKYO, Nov 30, 2020 - (JCN Newswire) - Eisai Co., Ltd. announced today that the company will present the latest data on its in-house discovered and developed anti-epileptic agent (AED) perampanel (product name: Fycompa), at the 74th American Epilepsy Society Annual Meeting (AES2020), to be held virtually from December 4 to 8, 2020.
A total of 43 poster presentations regarding perampanel are planned, including analysis results from the phase III clinical trial (FREEDOM/Study 342), which evaluated the effectiveness and safety of the perampanel monotherapy in the open-label extension (52 weeks) for epilepsy patients with partial onset seizures (POS) from 12 to 74 years of age without prior treatment history. Additionally, results from the phase III clinical trial Study 311 evaluating safety and tolerability of perampanel as an adjunctive therapy in pediatric epilepsy patients with POS or primary generalized tonic clonic (PGTC) seizures from 4 to less than 12 years of age will be presented.
Perampanel is a first-in-class AED discovered at Eisai's Tsukuba Research Laboratories. The agent is a highly selective, noncompetitive AMPA receptor antagonist that is postulated to reduce neuronal hyper-excitation associated with seizures by targeting glutamate activity at AMPA receptors on postsynaptic membranes. In Japan and the United States, perampanel is currently approved for monotherapy and adjunctive use in the treatment of POS (with or without secondarily generalized seizures) in patients with epilepsy 4 years of age and older, as well as adjunctive treatment for primary generalized tonic-clonic seizures in patients with epilepsy 12 years of age and older.
Eisai considers neurology, including epilepsy, a therapeutic area of focus. As we provide perampanel globally, Eisai pursues its mission to provide "seizure freedom" to a greater number of patients with epilepsy. Eisai seeks to address the diverse needs of, as well as increase the benefits provided to, patients with epilepsy and their families.
For more information, visit
https://www.eisai.com/news/2020/pdf/enews202080pdf.pdf
.
Source: Eisai
Sectors: BioTech
Copyright ©2025 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.
Related Press Release
Eisai and Merck & Co., Inc., Rahway, NJ, USA Provide Update on Phase 3 LEAP012 Trial in Unresectable, Non-Metastatic Hepatocellular Carcinoma
October 30 2025 13:43 JST
Merck & Co., Inc. and Eisai Announce WELIREG(R) (belzutifan) Plus LENVIMA(R) (lenvatinib) Met Primary Endpoint of Progression-Free Survival (PFS) in Certain Previously Treated Patients With Advanced Renal Cell Carcinoma
October 28 2025 23:30 JST
Health Canada Grants Authorization for "LEQEMBI(R)" (lecanemab) for the Treatment of Early Alzheimer's Disease
October 27 2025 13:23 JST
LEQEMBI(R) IQLIK(TM) (lecanemab-irmb) Subcutaneous Autoinjector Named to TIME's "Best Inventions of 2025"
October 14 2025 16:54 JST
Eisai and Biogen Announce U.S. Availability of LEQEMBI(R) IQLIK(TM) (lecanemab-irmb) Subcutaneous Injection Maintenance Dose for Treatment of Early Alzheimer's Disease
October 08 2025 11:03 JST
Eisai Highlights Breadth of Oncology Research at ESMO 2025
October 03 2025 17:01 JST
"LEQEMBI(R)" (lecanemab) IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease Approved in China
September 29 2025 09:33 JST
LEQEMBI(R) (Lecanemab) Approved for the Treatment of Alzheimer's Disease in Australia
September 24 2025 18:04 JST
Anti-MTBR (microtubule binding region) Tau Antibody Etalanetug Granted FDA Fast Track Designation
September 17 2025 17:20 JST
"New Answers to Dementia" Eisai Releases Concept Movie and New Content on Campaign Website for Dementia Month
September 12 2025 12:20 JST
More Press release >>
Latest Press Release
Hitachi Employee Receives the "Chop Wood Carry Water Award" from the Global OSS Organization CNCF for Leading the Establishment of Official Community in Japan
Nov 14, 2025 21:06 JST
The University of Osaka D3 Center and NEC Demonstrate Wide-Area Distributed Campus AI Processing Platform
Nov 14, 2025 00:41 JST
Toyota to Invest Up to $10 Billion Additional in Its U.S. Operations Over the Next Five Years
Nov 14, 2025 00:08 JST
MHI Thermal Systems Launches Magnetic Bearing Centrifugal Chiller "ETI-N" Series for Japanese Market
Nov 13, 2025 23:34 JST
MHI Completes Joint Demonstration with Kirin Group for Automation of Warehouse Operations, and Truck Loading and Unloading
Nov 13, 2025 23:00 JST
JCB launches second round of Shopping Mall Shuttle Free Ride Campaign in Guam
Nov 13, 2025 11:00 JST
NTT, NTT DOCOMO Establish the Large Action Model (LAM), an AI Technology to Accelerate 1-to-1 Marketing
Nov 12, 2025 19:00 JST
Mitsubishi Power Receives Second H-25 Gas Turbine Order for Chang Chun Petrochemical's Miaoli Factory in Taiwan
Nov 12, 2025 18:43 JST
All-New Delica Mini and eK Space Win RJC Car of the Year Award for 2026
Nov 12, 2025 18:00 JST
TANAKA PRECIOUS METAL TECHNOLOGIES Announces TK-SR Rhodium Material for Use in Probe Pins
Nov 12, 2025 11:00 JST
Hitachi and Tobu Railway launched a co-creation initiative to deliver HMAX on Japanese railways
Nov 11, 2025 17:35 JST
World Premiere of the New Hilux in Asia
Nov 10, 2025 20:29 JST
MHI Signs EPC Contract for Large-Scale Ammonia and Urea Fertilizer Production Complex for the State Concern Turkmenhimiya
Nov 10, 2025 19:51 JST
Mitsubishi Heavy Industries Announces Order Intake, Revenue, and Profit Growth in Strong 1H FY2025, Raises Full-Year Order Intake and Revenue Guidance
Nov 10, 2025 19:17 JST
MHI Reaches a Basic Agreement with J-POWER on the Transfer of its Domestic Onshore Wind Power Business
Nov 10, 2025 18:40 JST
JFCR and NEC Confirm Research Results for Developing Individualized Neoantigen Cancer Vaccines Using Whole-Genome Data
Nov 10, 2025 18:01 JST
NEC Wheelchair Singles Masters 2025 to begin
Nov 10, 2025 17:32 JST
Indicio Secures Investment from NEC X, Accelerating A New Era of User-Controlled Digital Identity
Nov 10, 2025 17:00 JST
The 18th JCB World Conference Held in Incheon, Republic of Korea
Nov 07, 2025 18:00 JST
Olympus Unveils Corporate Strategy
Nov 07, 2025 15:30 JST
More Latest Release >>